[{"address1": "1185 Avenue of the Americas", "address2": "3rd Floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "973 242 0005", "website": "https://www.synaptogen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alan J. Tuchman M.D., MBA(FAAN)", "age": 76, "title": "CEO & Director", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 303347, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel L. Alkon M.D.", "age": 81, "title": "President, Chief Scientific Officer & Director", "yearBorn": 1942, "fiscalYear": 2023, "totalPay": 375000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Weinstein", "age": 63, "title": "CFO, Executive VP, Treasurer & Secretary", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 568918, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.8, "open": 3.675, "dayLow": 3.55, "dayHigh": 3.73, "regularMarketPreviousClose": 3.8, "regularMarketOpen": 3.675, "regularMarketDayLow": 3.55, "regularMarketDayHigh": 3.73, "beta": 1.461, "forwardPE": -0.4745989, "volume": 5612, "regularMarketVolume": 5612, "averageVolume": 33688, "averageVolume10days": 19370, "averageDailyVolume10Day": 19370, "marketCap": 4377966, "fiftyTwoWeekLow": 3.269, "fiftyTwoWeekHigh": 16.25, "fiftyDayAverage": 4.13618, "twoHundredDayAverage": 5.125455, "currency": "USD", "enterpriseValue": -23066236, "floatShares": 1205433, "sharesOutstanding": 1233230, "sharesShort": 10481, "sharesShortPriorMonth": 7159, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0085, "heldPercentInsiders": 0.021429999, "heldPercentInstitutions": 0.0088599995, "shortRatio": 0.28, "shortPercentOfFloat": 0.0086, "impliedSharesOutstanding": 1233230, "bookValue": 20.321, "priceToBook": 0.17469613, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -12226578, "trailingEps": -23.32, "forwardEps": -7.48, "lastSplitFactor": "1:25", "lastSplitDate": 1712275200, "enterpriseToEbitda": 3.259, "52WeekChange": -0.7589134, "SandP52WeekChange": 0.24822903, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNPX", "underlyingSymbol": "SNPX", "shortName": "Synaptogenix, Inc.", "longName": "Synaptogenix, Inc.", "firstTradeDateEpochUtc": 1607437800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d14ff140-0ac6-3af9-a386-f918dc6aa47f", "messageBoardId": "finmb_268943522", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.55, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 28267756, "totalCashPerShare": 22.922, "ebitda": -7077351, "quickRatio": 4.487, "currentRatio": 4.576, "returnOnAssets": -0.13430001, "returnOnEquity": -0.15889, "freeCashflow": 1263834, "operatingCashflow": -5308938, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]